BITT has developed a platform for targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and the potent population of TNFR2 Tregs in the tumor microenvironment. The TNFR2 epitope is densely expressed on the immunosuppressive regulatory T cells (Tregs) in the tumor microenvironment that protect tumors and play a role in resistance to checkpoint inhibitors including PD1 and CTLA4. TNFR2 is also expressed on the surface of certain cancers as an NFkB-driven growth receptor oncogene. BITT has built a broad portfolio of intellectual property around targeting TNFR2 in oncology and has identified lead monoclonal antibody c and idates. BITT’s technology was developed at Massachusetts General Hospital and Harvard Medical School.

To download a complete overview of our oncology platform click here.